

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>BLICKENSTAFF KIM D</u> (Last) (First) (Middle) <u>C/O TANDEM DIABETES CARE, INC.</u> <u>11075 ROSELLE STREET</u> (Street) <u>SAN DIEGO CA 92121</u> (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol <u>TANDEM DIABETES CARE INC [ TNDM ]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)		
			3. Date of Earliest Transaction (Month/Day/Year) <u>03/15/2021</u>					
			4. If Amendment, Date of Original Filed (Month/Day/Year)			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/15/2021		S		135,934 <sup>(1)</sup>	D	\$87.1037 <sup>(2)</sup>	516,456	I	See Footnote <sup>(3)</sup>
Common Stock	03/15/2021		S		13,044 <sup>(1)</sup>	D	\$87.852 <sup>(4)</sup>	503,412	I	See Footnote <sup>(3)</sup>
Common Stock	03/16/2021		S		5,500 <sup>(1)</sup>	D	\$85.958 <sup>(5)</sup>	497,912	I	See Footnote <sup>(3)</sup>
Common Stock	03/16/2021		S		20,594 <sup>(1)</sup>	D	\$87.1887 <sup>(6)</sup>	477,318	I	See Footnote <sup>(3)</sup>
Common Stock	03/16/2021		S		23,828 <sup>(1)</sup>	D	\$88.1759 <sup>(7)</sup>	453,490	I	See Footnote <sup>(3)</sup>
Common Stock	03/16/2021		S		1,100 <sup>(1)</sup>	D	\$88.8536 <sup>(8)</sup>	452,390	I	See Footnote <sup>(3)</sup>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)					

Explanation of Responses:

- Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010.
- The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between \$86.64 to \$87.64. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
- The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010.
- The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between \$87.64 to \$88.16. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
- The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between \$85.58 to \$86.56. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
- The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between \$86.71 to \$87.70. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
- The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between \$87.71 to \$88.70. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
- The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between \$88.73 to \$88.99. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.

Remarks:

/s/ David B. Berger, Attorney-in-Fact for Kim D. Blickenstaff 03/17/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned hereby constitutes and appoints David B. Berger, Leigh A. Vosseller, Karrie Rexford, Christina X. Sun, James W. Sytsma and Ryan (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer of Tandem Diabetes Care, Inc. (the "Company"), (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to the undersigned. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform each and every act and thing whatsoever that may be necessary or desirable to complete and execute any such action. The undersigned agrees that each such attorney-in-fact may rely entirely on information furnished orally or in writing by the undersigned to the extent of the undersigned's knowledge.

DocuSign Envelope ID: EA16071A-6D90-4121-BCEE-147DF8DBCCCB

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4s and 5s with respect to the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 2nd day of March, 2021.

By:

Name: Kim D. Blickenstaff

DocuSign